Phil Wolfson
Phil Wolfson, MD, is a leading psychiatrist and psychotherapist known for his pioneering research in Ketamine and MDMA Assisted Psychotherapy. Author of The Ketamine Papers, he blends clinical expertise with decades of activism, writing, and teaching to transform mental health treatment.
Michael Alpert
Michael D. Alpert, MD, is a psychiatrist specializing in MDMA-assisted therapy. He works at South Cove Community Health Center in Boston and is affiliated with Harvard Medical School and the Trauma Research Foundation
Francis Guerriero
Francis Guerriero, MA, LICSW, is a private practice therapist in Cambridge, MA, with expertise in trauma therapy and MDMA-assisted treatment, working as part of The Trauma Research Foundation team.
Elizabeth Call
Elizabeth Call, Psy.D., is a clinical psychologist in private practice with a focus on trauma healing and integrative therapy. She is a team member of the MDMA-assisted psychotherapy study at the Trauma Research Foundation.
Anne St. Goar
Dr. Anne St. Goar, MD brings decades of clinical expertise and groundbreaking experience in MDMA-assisted psychotherapy. In this course, she explores trauma-informed care, psychedelic-assisted healing, and her work with the Boston MDMA Therapy team.
Daniel McQueen
Daniel McQueen, MA, is a leading psychedelic therapist and the author of Cannabis-Assisted Psychedelic Therapy for Trauma Resolution. As Executive Director of Medicinal Mindfulness, he is dedicated to advancing safe, intentional psychedelic healing practices.
William Richards
William Richards, Ph.D., is a pioneering psychologist at Johns Hopkins Bayview Medical Center, where he co-leads a groundbreaking program using psilocybin therapy for terminally ill cancer patients. He is also a featured contributor to the acclaimed documentary Fantastic Fungi.
Michael Mithoefer
Led by Dr. Michael Mithoefer, this course explores the clinical use of MDMA-assisted psychotherapy for treatment-resistant PTSD. Learn from a leading researcher who conducted the first FDA-approved trials and now oversees multisite Phase III studies across the U.S., Europe, and Israel.
